Centre intégré de santé et de services sociaux de l'Outaouais

Ouébec \* \*



# **ANTI-D**

## (Immunoglobulines human)

# Informations about pregnancy patients Rh negative or weak D other than type 1, 2 or 3 or Rh type 42

## WHAT IS HUMAN IMMUNOGLOBULIN?

It is a safe product obtained from the human plasma (blood) of several carefully selected donors. It contains specific antibodies directed against the antigen D (Rh-positive). This product is administered as a preventive treatment for certain problems related to pregnancy patients in Rh-negative or weak D other than type 1, 2 or 3 or Rh type 42.

#### WHY SHOULD I BE GIVEN THIS PRODUCT?

- During pregnancy or birth, the baby's red blood cells can pass into the mother's blood.
- This can also happen during a miscarriage, abortion, amniocentesis or an other bleeding from the placenta.
- When the blood of a fœtus from the RH-positive group enters the blood of an Rh-negative or weak D other than type 1, 2 or 3 or Rh type 42 mother, the mother's defence system (immune system) will view the fœtu's red cells as « strangers » and will start producing antibodies.
- These antibodies can penetrate the placenta, destroy the baby's red cells and cause more or less severe amaemia.
- Unfortunately, the antibodies formed in the mother's blood will remain there permanently, causing any future pregnancies to be considered high-risk.

As a precautionary measure, any Rh-negative or weak D other than type 1, 2 or 3 or Rh type 42 pregnant woman whose partner belongs to the Rh-positive (or unknown) group, will be given anti-D immunoglobulin

## How does human anti-D Immunoglobulin work?

The anti-D antibodies from human immunoglobulin target the baby's red blood cells in the mother's blood circulation and help to eliminate them. Their effectiveness is about 98%; **the mother, therefore, does not develop her own antibodies.** 

#### IS IT DANGEROUS FOR THE BABY?

Giving the mother human anti-D immunoglobulin will not create any danger for the baby. The product remains in the mother's blood and does not pass into the baby's blood. It is eliminated, moreover, after about 3 months.

## WHAT ARE THE RISK OF TRANSMITTING AN INFECTIOUS DISEASE?

Human immunoglolin is treated chemically in two stages and is then filtered to minimize the risk of transmitting any virus. No transmission of either a disease or a virus has been reported to date.

## WHEN SHOULD RECEIVE ANTI-D IMMUNOGLOBULIN?

- During each pregnancy.
  - Around the 28th week of pregnancy.
  - During the 72 hours following the birth of an Rh-positive baby.
- After a miscarriage, abortion, amniocentesis, or on the advice of a physician.

### How is administered?

Human anti-D Immunoglobulin can be administered intramuscular

## WHAT IF I DO NOT RECEIVE THE PRODUCT?

You should know that there are serious risks for you and your baby if you decide not to receive the product.

- Danger for the fœtus (anemia and jaundice) and for subsequent pregnancies.
- Moreover, if you develop your own anti-D antibodies, the laboratory could have difficulty in finding compatible blood for you if you should be in urgent need of blood.

At present there is no know effective alternative treatment.

### ARE THERE ANY SIDE EFFECTS?

Side effects are rare, but some people may feel discomfort or a slight swelling at the injection site, or be slightly feverish.

**However**, if you have had a reaction in the past to the administration of blood products, you should notify your doctor **Before** receiving this product.

## HOW DO I MAKE AN APPOINTMENT?

Your doctor will give you the G.A.R.E. Clinic referral form. You should then contact the CISSS de l'Outaouais hospital appointment service at 966-6350, where you will be given two appointments for the same day:

1st appointment: 7:15 A.M. at the outpatient labaratory for a blood test to detect any antibodies.

2<sup>nd</sup> appointment: 11 A.M. at the G.A.R.E. Clinic on the 3rd floor to receive your injection.

AS A PRECAUTIONARY MEASURE, YOU WILL BE KEPT UNDER OBSERVATION FOR **20 MINUTES** FOLLOWING THE ADMINISTRATION OF THE PRODUCT.

Références: monographie WinRho® SDF, Cangene corporation, Winnipeg Révisé: 2020-06-16